Repligen Corporation – Product Pipeline Review – H2 2011

Date: November 1, 2011
Pages: 57
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RBC7E508DFEEN
Leaflet:

Download PDF Leaflet

Repligen Corporation – Product Pipeline Review – H2 2011
Repligen Corporation – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Repligen Corporation - Product Pipeline Review - H2 2011” provides data on the Repligen Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Repligen Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Repligen Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Repligen Corporation - Brief Repligen Corporation overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Repligen Corporation human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Repligen Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Repligen Corporation’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Repligen Corporation’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Repligen Corporation in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Repligen Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Repligen Corporation.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Repligen Corporation and identify potential opportunities in those areas.
Repligen Corporation Snapshot
Repligen Corporation Overview
Key Information
Key Facts
Repligen Corporation – Research and Development Overview
Key Therapeutic Areas
Repligen Corporation – Pipeline Review
Pipeline Products by Stage of Development
Repligen Corporation – Pipeline Products Glance
Repligen Corporation – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Repligen Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Repligen Corporation–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Repligen Corporation – Drug Profiles
RG1068
RG2417
RG2833
RG3039
Repligen Corporation – Pipeline Analysis
Repligen Corporation – Pipeline Products by Therapeutic Class
Repligen Corporation - Pipeline Products By Target
Repligen Corporation – Pipeline Products by Route of Administration
Repligen Corporation – Pipeline Products by Molecule Type
Repligen Corporation – Recent Pipeline Updates
Repligen Corporation - Dormant Projects
Repligen Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
RG2133
Repligen Corporation – Locations And Subsidiaries
Head Office
Recent Developments
Oct 28, 2011: Repligen Provides Update On Phase I Trial For Families Of Spinal Muscular Atrophy Drug RG3039
Jun 23, 2011: Repligen Receives US Fast Track Designation And European Orphan Medicinal Product Recommendation For RG3039 In Spinal Muscular Atrophy
Jul 21, 2011: Repligen Initiates RG1068 Pilot Study To Improve Identification And Characterization Of Pancreatic Cancer
May 19, 2011: Repligen Receives FDA Approval To Initiate Phase I Clinical Trial Of RG3039 For Treatment Of Spinal Muscular Atrophy
Mar 14, 2011: Repligen Reports Positive Phase III Clinical Trial Results For RG1068 In Pancreatic Imaging
Mar 07, 2011: Repligen Reports Phase IIb Results For RG2417 For Bipolar Depression
Jun 01, 2011: Repligen Concludes Pre-NDA Meeting With FDA For RG1068
Financial Deals Landscape
Repligen Corporation, Deals Summary
Repligen Corporation, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Repligen Acquires Chromatography Technology Platform From BioFlash Partners
Partnerships
Repligen Expands Agreement With The Stanley Medical Research Institute
Repligen Enters Into Agreement With The Stanley Medical Research Institute
Licensing Agreements
Repligen Enters Into Licensing Agreement With UCI
Repligen Enters Into Licensing Agreement With Families of Spinal Muscular Atrophy
Repligen Enters Into Licensing Agreement With McLean Hospital
Repligen Enters Into Licensing Agreement With Bristol-Myers Squibb
ImClone Systems Enters Into Licensing Agreement With Repligen
Repligen Enters Into Licensing Agreement With The Scripps Research Institute
Repligen Enters Into Licensing Agreement With ChiRhoClin
Acquisition
Repligen To Acquire Novozymes Biopharma For $29 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Repligen Corporation – Pipeline by Therapy Area and Indication, H2 2011
Repligen Corporation – Pipeline by Stage of Development, H2 2011
Repligen Corporation – Phase III, H2 2011
Repligen Corporation - Phase II, H2 2011
Repligen Corporation - Phase I, H2 2011
Repligen Corporation - Pipeline By Therapeutic Class, H2 2011
Repligen Corporation - Pipeline By Target, H2 2011
Repligen Corporation – Pipeline By Route of Administration, H2 2011
Repligen Corporation – Pipeline By Molecule Type, H2 2011
Repligen Corporation – Recent Pipeline Updates, H2 2011
Repligen Corporation - Dormant Developmental Projects, 2010
Repligen Corporation - Discontinued Pipeline Products, 2010
Repligen Corporation, Deals Summary
Repligen Acquires Chromatography Technology Platform From BioFlash Partners
Repligen Expands Agreement With The Stanley Medical Research Institute
Repligen Enters Into Agreement With The Stanley Medical Research Institute
Repligen Enters Into Licensing Agreement With UCI
Repligen Enters Into Licensing Agreement With Families of Spinal Muscular Atrophy
Repligen Enters Into Licensing Agreement With McLean Hospital
Repligen Enters Into Licensing Agreement With Bristol-Myers Squibb
ImClone Systems Enters Into Licensing Agreement With Repligen
Repligen Enters Into Licensing Agreement With The Scripps Research Institute
Repligen Enters Into Licensing Agreement With ChiRhoClin
Repligen To Acquire Novozymes Biopharma For $29 Million

LIST OF FIGURES

Repligen Corporation – Pipeline by Therapy Area and Indication, H2 2011
Repligen Corporation – Pipeline by Stage of Development, H2 2011
Repligen Corporation – Pipeline By Therapeutic Class, H2 2011
Repligen Corporation - Pipeline By Target, H2 2011
Repligen Corporation – Pipeline By Route of Administration, H2 2011
Repligen Corporation – Pipeline By Molecule Type, H2 2011

Ask Your Question

Repligen Corporation – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: